Literature DB >> 12297992

Systemic candidiasis in intensive care units: a multicenter, matched-cohort study.

Ghislaine Leleu1, Philippe Aegerter, Bertrand Guidet.   

Abstract

OBJECTIVE: To determine the impact of systemic candidiasis on the mortality and length of hospital stay of intensive care unit (ICU) patients and the associated workload.
DESIGN: Multicenter, retrospective, matched-cohort study.
SETTING: Data were retrieved from a computerized database that prospectively collected clinical data submitted by 32 ICUs in the Paris, France area. PATIENTS: A total of 149 stays with systemic candidiasis, including 104 candidemia, on ICU admission were identified in a 3-year period (1995-1997) among 49,063 admissions (3 per 1,000 admission). A total of 121 cases were matched with patients with no evidence of systemic Candida infection during the hospitalization period under study (same ICU, date of ICU admission, age, sex, simplified acute physiology score (SAPS II), location of the patient before admission, type of admission).
RESULTS: Patients with systemic candidiasis had longer ICU length of stays than controls (25 vs 10 d; P =.001) with a relative risk for death of 2.27 (95% confidence interval, 1.64-3.11; P =.001). There was no difference between patients with systemic candidiasis with or without positive blood culture.
CONCLUSIONS: Systemic Candida infections increased mortality and morbidity in severely ill patients. Optimizing management of such infections is imperative. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Year:  2002        PMID: 12297992     DOI: 10.1053/jcrc.2002.35815

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  36 in total

1.  Estimating attributable mortality of candidemia: clinical judgement vs matched cohort studies.

Authors:  S I Blot; K H Vandewoude
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-02-18       Impact factor: 3.267

Review 2.  Prophylaxis and treatment of invasive candidiasis in the intensive care setting.

Authors:  L Ostrosky-Zeichner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-10       Impact factor: 3.267

3.  Invasive devices: no need? No use!

Authors:  Stijn I Blot; Renaat Peleman; Koenraad H Vandewoude
Journal:  Intensive Care Med       Date:  2006-12-05       Impact factor: 17.440

Review 4.  Epidemiology, incidence and risk factors for invasive candidiasis in high-risk patients.

Authors:  Ercole Concia; Anna Maria Azzini; Michela Conti
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 5.  Clinical aspects of invasive candidiasis in critically ill patients.

Authors:  Mariano Pennisi; Massimo Antonelli
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 6.  Invasive fungal infections in transplant recipients.

Authors:  Jose A Vazquez; Marisa H Miceli; George Alangaden
Journal:  Ther Adv Infect Dis       Date:  2013-06

Review 7.  Surface glycans of Candida albicans and other pathogenic fungi: physiological roles, clinical uses, and experimental challenges.

Authors:  James Masuoka
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

8.  Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?

Authors:  Rafael Zaragoza; Javier Pemán; Miguel Salavert; Angel Viudes; Amparo Solé; Isidro Jarque; Emilio Monte; Eva Romá; Emilia Cantón
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

Review 9.  Management of invasive candidiasis in critically ill patients.

Authors:  Stijn Blot; Koenraad Vandewoude
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Potentiation of azole antifungals by 2-adamantanamine.

Authors:  Michael D Lafleur; Lingmei Sun; Ida Lister; John Keating; Andre Nantel; Lisa Long; Mahmoud Ghannoum; Jeffrey North; Richard E Lee; Ken Coleman; Thomas Dahl; Kim Lewis
Journal:  Antimicrob Agents Chemother       Date:  2013-05-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.